FDA approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month Published on 02/17/2026 at 08:01 am EST PRNewswire Share JOHNSON & JOHNSON -0.08% Monthly dosing reduces treatment visits while maintaining established...
BackgroundLymph node metastasis is a critical event in the progression of EGFR wildtype lung adenocarcinoma (LUAD), a subtype lacking effective targeted ther 1 Introduction Lung adenocarcinoma (LUAD) is the most common histological form of non-small cell lung cancer (NSCLC). Approximately...
AbstractBackground Pulmonary adenocarcinoma is one of the most common types of lung cancer and accounts for approximately 12.6% of all cancer-related deaths. Epidermal growth factor receptor (EGFR) mutation subtypes are clinically relevant for determining prognosis and guiding first-line EGFR tyrosine...
Abstract The epidermal growth factor receptor (EGFR) plays a crucial role in cancer cell signaling, making it a significant target in anticancer therapies. However, current EGFR inhibitors often face limitations, such as treatment resistance and toxicity. Ginkgo biloba is a...
Correction to: Nature https://doi.org/10.1038/nature14969 Published online 30 September 2015 In Extended Data Fig. 8 of this article, a micrograph shown in the left column (panel AZD) was inadvertently duplicated during figure preparation. The intended image was meant to show phospho-ERK...
